16-23 of 23
Latest TROP2 ADC Approval for HR+ HER2- Metastatic Breast Cancer
Medical Industry FeatureLatest TROP2 ADC Approval for HR+ HER2- Metastatic Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP
Komal Jhaveri, MD, FACP
Vanessa Soto-Romano
Managing Eye-Related Adverse Events Caused by Cancer Treatments
Medical Industry FeatureManaging Eye-Related Adverse Events Caused by Cancer Treatments
Neel D. Pasricha, MD
MIRASOL Insights in PROC: A Biomarker-Driven Approach
Project Oncology®MIRASOL Insights in PROC: A Biomarker-Driven Approach
Charles Turck, PharmD, BCPS, BCCCP
Cecelia Boardman, MD
New Trial Device Opens Blood-Brain Barrier to Treat Glioblastoma
Medical Industry FeatureNew Trial Device Opens Blood-Brain Barrier to Treat Glioblastoma
Brian Gill, M.D.
Rise in Early-Onset Colon Cancer Being Studied Through Single-Cell Sequencing
Medical Industry FeatureRise in Early-Onset Colon Cancer Being Studied Through Single-Cell Sequencing
Joel Gabre, M.D, MPH
Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma
Medical Industry FeatureBiomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma
Mateo Mejia Saldarriaga, M.D.
- advertisement
An Exploration of Multiple Myeloma Treatments
Project Oncology®An Exploration of Multiple Myeloma Treatments
Key Considerations for G-CSF Administration in Patients with FN Risk
Medical Industry FeatureKey Considerations for G-CSF Administration in Patients with FN Risk
Charles Turck, PharmD, BCPS, BCCCP
Arielle Heeke, MD
